Posts

Merck KGaA Discontinues Two Cancer Drug Trials After Failures

on

Sanofi Discontinues mRNA Seasonal Flu Vaccine Development, Focuses on Existing Vaccines Amid CEO Confidence

on

Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana

on

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

on

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

on

Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift

on

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

on

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

on

Cassava Sciences Discontinues Alzheimer's Program After Simufilam Fails Second Phase 3 Trial

on

Lava cuts jobs by 30% after key drug discontinued

on

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field

on

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

on

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

on

Cargo Therapeutics Discontinues Lead CAR-T Program Due to Poor Durability and Safety Concerns

on